Results for "CAR-T therapy"

The $7.8 Billion Bet: Why Gilead's Arcellx Buyout Signals the Death of the Solo CAR-T Dream

Gilead's massive $7.8bn acquisition of Arcellx isn't just about pipeline depth; it’s a brutal market consolidation signal in the competitive **biotech M&A** landscape.